莱博雷生有几种规格?多少钱?

Leborexan is a new drug for the treatment of insomnia. Its specification selection, price range and medication precautions are important basis for patients to formulate treatment plans. The drug developed by Japan's Eisai Company works by accurately regulating the sleep-wake cycle. Different specifications correspond to differentiated treatment needs, and clear medication guidelines can minimize potential risks.

Lebrasant comes in several specifications

Japanese Eisai’s version of Lebrasant is available in three dosage sizes of 2.5mg, 5mg and 10mg, covering a variety of clinical needs from mild insomnia to intractable sleep disorders. The tablets adopt film coating technology to ensure drug stability and rapid disintegration properties. The selection of specifications requires comprehensive consideration of the patient's age, liver and kidney function, and symptom severity. Doctors usually recommend starting with a low dose and gradually adjusting it.

Dosage Specifications and Applicable Scenarios

The 2.5 mg specification is suitable for first-time medication patients or elderly groups, which can reduce the risk of drowsiness during initial medication; the 5 mg specification is the mainstream treatment dose and meets the long-term management needs of most patients; the 10 mg high-dose version is mainly used for stubborn insomnia cases where traditional drugs are insufficiently effective. All specifications are packaged in aluminum-plastic blister packaging, with a standard configuration of 30 tablets/box for easy dose tracking.

How much does Lebraxen cost in different specifications?

Prices of different specifications

The price gradient of Lebraxen is positively related to dose intensity. The 2.5mg specification is priced at approximately US$77/box, the 5mg (100 tablets) is US$117/box, and the 10mg specification is US$165/box. The price difference results from the synergy of active ingredient content, production costs and packaging specifications.

Regional price fluctuation patterns

Sales prices in Japan are relatively stable, with small fluctuations. In the international market, drug prices may rise due to cold chain transportation, tariff effects, etc.

Precautions for lebraxane

The use of lebraxane must strictly follow the medication specifications. Special physiological conditions and comorbid diseases may affect the treatment effect or increase risks. A symptom monitoring mechanism should be established during medication to detect and deal with abnormal reactions in a timely manner.

Sleep-related abnormalities

A small number of patients report symptoms of sleep paralysis, which manifests as temporary inability to move limbs in the early stages of awakening, usually lasting 30-120 seconds. A few patients develop complex sleep behaviors, including unconscious eating or walking, and it is recommended that sharp objects be removed from the bedroom environment. These phenomena mostly occur in the early stages of treatment, and the incidence decreases after 2 weeks of continued medication.

Respiratory and mental health risks

Patients with chronic obstructive pulmonary disease (COPD) may have a decrease in blood oxygen saturation after taking medication, and it is recommended to use blood oxygen monitoring equipment at night. Among patients with depression, very few patients experience increased suicidal ideation and require weekly PHQ-9 scale assessments. Patients with impaired respiratory function should avoid combined use with opioids to prevent additive respiratory depressant effects.

Comorbidity assessment and medication monitoring

Polysomnography must be completed before the first prescription to rule out potential diseases such as sleep apnea. Those who do not show significant effects after 7-10 days of treatment should be re-evaluated for diagnosis. Drug-resistant cases may have unrecognized thyroid dysfunction. It is recommended to recheck liver enzyme indicators every 3 months.